An aerial photo of the National Exhibition and Convention Center (Shanghai), the main venue for the seventh CIIE [Photo/sinopharm.com]

Deepening Cooperation on Industrial and Supply Chains for High-quality Development of Enterprises, a sub-forum hosted by the State-owned Assets Supervision and Administration Commission of the State Council and China’s Ministry of Commerce, took place in Shanghai on Nov 6.

Deepening Cooperation on Industrial and Supply Chains for High-quality Development of Enterprises, a sub-forum of the seventh Hongqiao International Economic Forum, takes place on Nov 6, 2024. [Photo/sinopharm.com] 

The event was part of the seventh Hongqiao International Economic Forum, which serves as a key component of the seventh China International Import Expo (CIIE).

Hu Jianwei, deputy general manager of China National Pharmaceutical Group Co Ltd (Sinopharm) and head of the Sinopharm delegation, was invited to attend the sub-forum.

On Nov 7, Hu and his delegation toured the booths of Sinopharm’s key CIIE partners, including Medtronic, Abbott, Fresenius Medical Care, FANCL, Edwards Lifesciences, Seragon, Elekta, GE HealthCare and Linatech LLC. During the visits, they engaged in discussions with company representatives, gaining insights into the latest products and technologies.

At the booths of Siemens Healthineers and Fosun Pharma, Hu exchanged ideas with corporate leaders on initiatives for open collaboration and mutual growth.

Participants pose for a photo at the signing ceremony of Sinopharm at the seventh CIIE on Nov 7, 2024. [Photo/sinopharm.com]

Later that day, Sinopharm signed 20 procurement agreements with world-leading medical device and healthcare companies. The agreements achieved record-breaking transaction amounts and scales, marking significant progress for Sinopharm in high-end medical equipment manufacturing, medical devices and imported health and nutritional products.

Since its first participation in the CIIE in 2018, Sinopharm has consistently secured outstanding results, with a compound annual growth rate of 25 percent in contract value. The company continues to rank among the top in import contracts within the pharmaceutical and medical device sectors, demonstrating its commitment to sharing opportunities in China's healthcare industry and leading the way toward a more open, inclusive, balanced and mutually beneficial growth model.

Over seven years of active involvement, Sinopharm has established the CIIE as a crucial platform for fostering international collaboration. The group has leveraged this event to broaden its global perspective, expand partnerships and enhance its market presence.

This year’s CIIE saw Sinopharm deepen relationships with long-term partners and forge connections with new ones, achieving higher-level, broader and more impactful collaborations. The company has also introduced high-quality, innovative products to the Chinese market, driving sustainable development in the healthcare industry.

Looking ahead, Sinopharm is committed to further strengthening global partnerships, facilitating demand-supply alignment in the market and advancing industrial sustainability. By bringing cutting-edge medical products to China, it aims to support the Healthy China 2030 Initiative and safeguard the health and well-being of people nationwide.